Last reviewed · How we verify
LTX-109 2 %
At a glance
| Generic name | LTX-109 2 % |
|---|---|
| Sponsor | Lytix Biopharma AS |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus (PHASE2)
- A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus (PHASE1, PHASE2)
- A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo (PHASE2)
- A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA) (PHASE1, PHASE2)
- A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTX-109 2 % CI brief — competitive landscape report
- LTX-109 2 % updates RSS · CI watch RSS
- Lytix Biopharma AS portfolio CI